Advanced cerebral monitoring in neurocritical care

Nobl Barazangi, J. Claude Hemphill III
Department of Neurology, University of California, San Francisco and Neurocritical Care Program, San Francisco General Hospital, California, USA

Introduction

Monitoring the brain after acute injury is central to the practice of neurocritical care for patients with a wide range of disorders including traumatic brain injury (TBI), ischemic and hemorrhagic stroke, as well as status epilepticus and acute brain infections. While historically the most widely available monitor has been the bedside clinical neurological examination, there has long been recognition that additional measures of intracranial pressure (ICP) and cerebral perfusion pressure (CPP) may augment clinical assessment or even supersede it. Current neuromonitoring techniques involve a range of tools that have evolved from the study of cerebral physiology and advances in the understanding of the pathophysiology of acute brain injury. These techniques have focused on the measurement of cerebral physiologic and metabolic parameters with the goal of improving the detection and management of primary and secondary brain injury in patients who have suffered TBI, stroke, subarachnoid hemorrhage (SAH), or have had neurosurgical procedures.[1-3] Some neuromonitoring techniques have been available for many years and have become established tools in the care of neurocritically ill patients, such as ICP and cerebral perfusion pressure (CPP) monitoring and electroencephalography (EEG).[1-4-6] Our improved understanding of cellular and molecular disturbances that occur post-injury, in addition to technological advancements that allow for continuous, quantitative, and ‘real-time’ measurements, has led to the development of newer techniques that can detect cerebral metabolic disturbances, such as brain tissue oxygen monitoring and cerebral microdialysis.[1-3,6-8]

The development of new neuromonitoring techniques has been particularly important because standard monitoring techniques, such as ICP and CPP measurements, may be insufficient in detecting subtle manifestations of brain injury or are poor...
surrogates for physiologic parameters of interest. For example, CPP may not be a reliable method to measure cerebral blood flow. The more recently developed neuromonitoring techniques reviewed here, including cerebral blood flow (CBF) monitoring techniques, brain tissue oxygen tension (P$_{\text{btO}_2}$) and jugular bulb venous oxygen saturation (SjVO$_2$) monitoring, and cerebral microdialysis, may provide more detailed information regarding cerebral metabolic function. Ideally, these measurements would provide information that is of prognostic utility as well as help direct management of the neurocritically ill patient in order to improve clinical outcome. Even as many of these tools are now becoming integrated into regular neurocritical care, research is ongoing to determine the validity, reliability, and utility of these techniques in the clinical management of patients and in predicting and potentially improving clinical outcome.

Additionally, as new neuromonitors have increased the volume and complexity of data available for assessment and management of the neurocritically ill patient, questions regarding methods of interpretation of this new data have justifiably arisen. It is becoming increasingly evident that our initial approaches to neuromonitoring, where information obtained from a single modality is interpreted independently from other cerebral and systemic physiologic and metabolic parameters, are likely overly simplistic. New methods of data collection and analysis, as well as advanced informatics techniques, are currently being developed to learn how to logically integrate neuromonitoring data, and have proven to be useful in discovering new interpretations of previously collected data.

**Brain tissue oxygen monitoring**

The new advanced neuromonitoring opportunity with which there is the most familiarity is the ability to directly measure brain tissue oxygen tension (P$_{\text{btO}_2}$). P$_{\text{btO}_2}$ monitoring allows direct measurement of focal tissue oxygen tension in a specific region of the brain. This presumably provides a measure of oxygen content or delivery which may be relevant in the assessment of secondary brain injury due to ischemia or impaired microvascular perfusion [Figure 1]. Two principal devices have been used in recent studies: the LICOX system (Integra Neurosciences, Plainsboro, NJ) which uses a polarographic Clarke-type microelectrode and the NeuroTrend system (Codman and Shurtleff, Raynham, MA) which uses optical luminescence. However, the LICOX system (Integra Neurosciences, Plainsboro, NJ) is currently the only commercially available P$_{\text{btO}_2}$ monitoring system. In this system, the P$_{\text{btO}_2}$ probe is placed directly into the brain parenchyma usually with a fixed cranial bolt, approximately 2-3 cm below the dura, targeting frontal white matter. Brain temperature is measured concurrently with the same probe. Optimal probe placement location remains a point of controversy. Our approach is to place the probe in the hemisphere ipsilateral to a focal injury (such as non-traumatic ICH or a region at risk for vasospasm after aneurysmal SAH) and place the probe in the least injured hemisphere in the context of diffuse injury such as with head trauma [Figure 2].

Interpretation and clinical application of P$_{\text{btO}_2}$ monitoring data continues to be investigated; however, numerous observational studies have suggested specific P$_{\text{btO}_2}$ thresholds which may be associated with worsened outcome after TBI and SAH, and in other forms of brain injury as well. Initial impressions were that P$_{\text{btO}_2}$ monitoring would provide a specific disease-independent ischemic threshold. However, this has been shown to likely be an oversimplification as P$_{\text{btO}_2}$ may vary with a number of physiological parameters such as inspired oxygen concentration (FIO$_2$), CBF, and perhaps cerebral perfusion pressure. Even so, a P$_{\text{btO}_2}$ level below 10-15 mmHg has generally been the threshold identified at which outcome is worsened and some authors have referred to this as an “ischemic threshold.” One study using positron emission tomography (PET) suggested a P$_{\text{btO}_2}$ of 14 mmHg as the threshold at which critical oxygen extraction occurs.

Several experimental studies have assessed the correlation of P$_{\text{btO}_2}$ with other measures of brain oxygenation such as jugular bulb venous oxygen saturation. Finding a clear-cut relationship between P$_{\text{btO}_2}$ and CBF and cerebral oxygen extraction, which are important factors in determining cerebral metabolic rate of oxygen (CMRO$_2$), has been more challenging. P$_{\text{btO}_2}$ measurements have been shown to positively correlate with arterial oxygen tension, FIO$_2$, mean arterial pressure, CPP, CBF, hemoglobin concentration, and inversely with oxygen extraction fraction on PET and mean transit time on dynamic CT perfusion (CTP). Experimental studies have shown a linear correlation between P$_{\text{btO}_2}$ and changes in end-tidal carbon dioxide measurements or CBF, and a sinusoidal correlation with mean arterial pressure, suggesting that P$_{\text{btO}_2}$ is influenced by factors that regulate CBF and cerebral autoregulation. Furthermore, hyperventilation has been shown to decrease P$_{\text{btO}_2}$ and this is presumably mediated through a primary reduction in CBF due to cerebral vasoconstriction. Poor oxygen reactivity testing, in which P$_{\text{btO}_2}$ does not increase to the expected degree in response to an increase in FIO$_2$, may indicate poor autoregulation and be associated with worsened outcome. Data is varied regarding the relationship between P$_{\text{btO}_2}$ and ICP; in general P$_{\text{btO}_2}$ decreases with increased ICP only when CPP is concurrently decreased, suggesting that P$_{\text{btO}_2}$ relates principally to measures of cerebral perfusion. Significantly decreased P$_{\text{btO}_2}$ has

---

Barazangi and Hemphill III: Cerebral monitoring techniques

Neurology India | October-December 2008 | Vol 56 | Issue 4
been correlated to an elevated lactate/pyruvate ratio in addition to other biochemical alterations found during cerebral microdialysis, but a consistent $P_{btO_2}$ threshold at which deleterious effects in cerebral metabolism occur remains elusive.\cite{13,25-28} Because CBF may be low in the setting of flow-metabolism uncoupling due to the primary injury or the administration of sedative medications, a low $P_{btO_2}$ does not always mean ischemia (e.g., induced hypometabolism) and a high $P_{btO_2}$ may be pathologically abnormal (e.g., hyperemia).\cite{10} This suggests that $P_{btO_2}$ must be considered in the context of other physiological parameters rather than necessarily superseding other values.

While many observational studies have investigated the relationship between $P_{btO_2}$ and clinical outcome in patients with TBI, SAH, and, to a lesser extent, intracerebral hemorrhage (ICH), it is important to recognize that to date no randomized, controlled trials have been performed to assess the impact of $P_{btO_2}$ monitoring or $P_{btO_2}$-directed therapy on clinical outcome [Table 1]. Several studies in patients with TBI have shown that patients with $P_{btO_2}$ levels less than 10-15 mmHg for extended periods of time or on multiple occasions have an increased rate of morbidity and mortality.\cite{29-32} The finding of a dose-response relationship in which duration and severity of low $P_{btO_2}$ is associated with long-term mortality suggests that low $P_{btO_2}$ is a reasonable target for intervention.\cite{30} Additionally, in one study patients with severe TBI who were managed with $P_{btO_2}$-guided therapy (goal $P_{btO_2} > 25$ mmHg) had a lower risk of mortality than historical controls managed with conventional ICP and CPP monitoring. However, it remains unclear whether this improvement was related exclusively to cerebral oxygenation or whether it might reflect overall improvements in neurocritical care. Other similar studies showed an equivocal response in outcome to $P_{btO_2}$-guided therapy.\cite{33,34} Correlations between lower $P_{btO_2}$ levels and poor performance on neuropsychological and cognitive testing after head trauma have also been observed.\cite{35} In aneurysmal SAH, oxygen reactivity index (ORx), defined as a moving correlation coefficient between CPP and $P_{btO_2}$, was predictive of symptomatic vasospasm whereas absolute values of ICP, CPP, and $P_{btO_2}$ were not.\cite{36} Taken together, this growing collection of evidence strongly suggests that $P_{btO_2}$ levels are associated with short-term events of impaired cerebral oxygenation and long-term clinical outcome. However, in order for the field of advanced neuromonitoring to take the next substantial step forward, prospective controlled clinical trials are necessary to demonstrate that $P_{btO_2}$ is not just a prognostic marker, but rather a modifiable factor which can lead to improved outcome.

Barazangi and Hemphill III: Cerebral monitoring techniques


Figure 2: Representative non-contrast head computed tomography (CT) scan showing $P_{O_2}$ monitor placement and $P_{O_2}$ levels over time in two separate patients. (A), Non-contrast head CT from a patient with traumatic brain injury demonstrating the tip of the brain tissue oxygen probe (white arrow) in the left hemisphere white matter. (B), $P_{O_2}$ profile early after placement in a patient with intracerebral hemorrhage (probe placed ipsilateral to hematoma). Continuous $P_{O_2}$ levels are shown; values are not considered reliable until stabilization at 1-2 h post-placement. The shaded region represents inspired oxygen concentration. Increases in per cent inspired oxygen to 100% results in an appropriate increase in the $P_{O_2}$ level, indicating a functioning probe.
### Table 1: Brain oxygen monitoring, ischemic thresholds, and clinical outcomes

<table>
<thead>
<tr>
<th>Study</th>
<th>Disorder</th>
<th>Number of patients</th>
<th>Method</th>
<th>Threshold</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gopinath, et al.; 1994</td>
<td>TBI</td>
<td>167</td>
<td>SjvO₂</td>
<td>&lt;50% for more than 10 min</td>
<td>Early SjvO₂ desaturations were significantly related to poor neurological outcomes (90% of patients with multiple desaturations, 74% of patients with one desaturation, compared to 55% of patients without desaturations)</td>
</tr>
<tr>
<td>Robertson, et al.; 1995</td>
<td>TBI</td>
<td>177</td>
<td>SjvO₂</td>
<td>&lt;50%</td>
<td>One or more episode of desaturation was strongly associated with poor neurological outcome</td>
</tr>
<tr>
<td>Keining, et al.; 1997</td>
<td>TBI, ICH</td>
<td>21 TBI, 2 ICH</td>
<td>PₐO₂</td>
<td>&lt;10 mmHg</td>
<td>Ischemic episode of &lt;10 mmHg for &gt;15 min always associated with poor neurological outcome</td>
</tr>
<tr>
<td>Valadka, et al.; 1998</td>
<td>TBI</td>
<td>43</td>
<td>PₐO₂</td>
<td>&lt;15 mmHg</td>
<td>The longer duration of PₐO₂ &lt;15 mmHg, or any duration of PₐO₂ &lt;6 mmHg, the greater likelihood of death</td>
</tr>
<tr>
<td>Bardt, et al.; 1998</td>
<td>TBI</td>
<td>35</td>
<td>PₐO₂</td>
<td>&lt;10 mmHg</td>
<td>56% patients with PₐO₂ &lt;10 mmHg for &gt;300 min died, 22% had poor outcome, 22% had favorable outcome at six months</td>
</tr>
<tr>
<td>Dings, et al.; 1998</td>
<td>TBI</td>
<td>35</td>
<td>PₐO₂</td>
<td>&lt;10 mmHg</td>
<td>35.5% of patients with bad outcome (GOS 1-3 at six months) had PₐO₂ &lt;10 mmHg in first 24 h, compared to 10.6% in good outcome group (GOS 4-5 at six months)</td>
</tr>
<tr>
<td>Cruz, et al.; 1998</td>
<td>TBI</td>
<td>178 (SjvO₂ group), 175 (CPP group)</td>
<td>SjvO₂</td>
<td>&lt;50%</td>
<td>Patients with additional SjvO₂ monitoring had improved mortality and outcome (GOS) compared to patients with only CPP monitoring (historical controls)</td>
</tr>
<tr>
<td>Cormio, et al.; 1999</td>
<td>TBI</td>
<td>450 (19.1% had SjvO₂ &gt;75 mmHg)</td>
<td>SjvO₂</td>
<td>&gt;75%</td>
<td>Patients with SjvO₂ &gt;75% had a significantly increased risk of death, persistent vegetative state, or severe disability than in patients with normal SjvO₂</td>
</tr>
<tr>
<td>Van der Brink, et al.; 2000</td>
<td>TBI</td>
<td>101</td>
<td>PₐO₂</td>
<td>&lt;5, 10, 15 mmHg</td>
<td>All PₐO₂ levels associated with poor outcome (GOS), and relative risk of death increases with lower PₐO₂ thresholds</td>
</tr>
<tr>
<td>Vath, et al.; 2001</td>
<td>TBI</td>
<td>51</td>
<td>PₐO₂</td>
<td>&lt;5 mmHg</td>
<td>PbtO₂ &lt;5 mmHg significantly related to poor outcome (GOS 1-3) at &lt;6 h after trauma</td>
</tr>
<tr>
<td>Macmillan, et al.; 2001</td>
<td>TBI</td>
<td>75</td>
<td>SjvO₂</td>
<td>&gt;75% or &lt;54%</td>
<td>Larger proportion of patients with poor outcome (GOS 1-3) at 12 months had a SjvO₂ level of &lt;54% or &gt;75% for longer duration than those with good outcome (GOS 4-5)</td>
</tr>
<tr>
<td>van Santbrink, et al.; 2003</td>
<td>TBI</td>
<td>41</td>
<td>PₐO₂ /TOR</td>
<td>--</td>
<td>In the first 24 h, higher mean TOR (response of PₐO₂ to changes in arterial PO₂) was associated with worse outcome (GOS) at six months</td>
</tr>
<tr>
<td>Meixensberger, et al.; 2003 (J Neurol Neurosurg Psychiatry)</td>
<td>TBI</td>
<td>53 (PₐO₂ group), 40 (ICP/CPP group)</td>
<td>PₐO₂</td>
<td>&lt;10 mmHg</td>
<td>More patients with ICP/CPP-guided, as opposed to PₐO₂-guided therapy, had significantly decreased PₐO₂, but there was no significant difference in outcome between the two groups</td>
</tr>
<tr>
<td>Meixensberger, et al.; 2003 (Neurol Res)</td>
<td>SAH</td>
<td>42</td>
<td>PₐO₂</td>
<td>&lt;10 mmHg</td>
<td>For total monitoring time and last day of monitoring, but not other periods of monitoring (e.g., total monitoring time without last two days or second to last monitoring day), there was a significant difference in PₐO₂ in nonsurvivors (GOS 1) versus survivors (GOS 3-5)</td>
</tr>
<tr>
<td>Meixensberger, et al.; 2004</td>
<td>TBI</td>
<td>40</td>
<td>PₐO₂</td>
<td>&lt;15 mmHg</td>
<td>Patients with PₐO₂ &lt;15 mmHg had worse outcome in memory, speech, and intelligence testing</td>
</tr>
<tr>
<td>Stiefel, et al.; 2005</td>
<td>TBI</td>
<td>28 (PₐO₂ group), 25 (ICP/CPP group)</td>
<td>PₐO₂</td>
<td>&lt;25 mmHg</td>
<td>Patients with PₐO₂ monitoring had significantly reduced mortality rate of 25% compared to 44% in patients with conventional ICP and CPP monitoring (historical controls)</td>
</tr>
<tr>
<td>Stiefel, et al.; 2006</td>
<td>TBI</td>
<td>25</td>
<td>PₐO₂</td>
<td>&lt;10, 20 mmHg</td>
<td>Despite optimal ICP/CPP levels, 47% of patients had PₐO₂ &lt;20 mmHg and 21% had PₐO₂ &lt;10 mmHg, and mortality rate is higher in patients with reduced PₐO₂</td>
</tr>
<tr>
<td>Jaeger, et al.; 2007</td>
<td>SAH</td>
<td>67</td>
<td>PₐO₂ /ORx</td>
<td>--</td>
<td>The index of PₐO₂ pressure reactivity (ORx) was significantly higher in the delayed cerebral infarction group (20 patients), and ORx values on SAH Day 5 and 6 carried predictive value for the occurrence of delayed infarction</td>
</tr>
</tbody>
</table>

Barazangi and Hemphill III: Cerebral monitoring techniques
homogeneous white matter may mitigate this to some degree. Finally, placement of the probe involves an invasive procedure, albeit one that has been associated with relatively few complications of hemorrhage or infection even when compared with routine ICP monitoring using a ventricular catheter.[13] Future clinical uses of \( P_{ti}O_2 \) monitoring include additional investigations evaluating patients with hemorrhagic stroke[16,37-39] or brain death.[40,41]

### Jugular bulb venous oxygen saturation

Measurement of the venous oxygen saturation in the jugular bulb as blood is exiting the brain provides a measure of global cerebral oxygen delivery. It also provides a way to estimate the global relationship between CBF and metabolism, with the goal of detecting cerebral hypoperfusion or hyperperfusion and thereby preventing and treating secondary ischemic brain injury.[8,13,42,43] \( SjvO_2 \) is measured with a catheter that is placed by retrograde cannulation of the internal jugular vein until the catheter is at or near the jugular bulb, usually at the first to second cervical vertebrae and above the level where contamination from extracranial venous blood may occur.[42,43] Commercially available catheters have a fiberoptic sensor that continuously measures the blood oxygen saturation, and a small lumen from which blood can be withdrawn for venous blood gas testing. This allows calibration of the catheter as well as calculation of the venous blood oxygen content \( (C_vO_2) \) and subsequently the cerebral arteriovenous oxygen difference \( (AVDO_2) \). As with \( P_{ti}O_2 \) measurements, whether to cannulate the injured or uninjured side remains a topic of debate; our approach is to cannulate the dominant jugular vein if not limited by neck or other injuries.[8,13] The accuracy of \( SjvO_2 \) monitors has been confirmed by several studies.[42,44,45] Complications from \( SjvO_2 \) monitoring are rare, but include carotid puncture, thrombosis, infection, and hematoma formation.

\( SjvO_2 \) is inversely related to the \( AVDO_2 \). If the cerebral \( AVDO_2 \) increases because the brain is extracting more oxygen, then the \( SjvO_2 \) decreases, and vice versa. The normal \( SjvO_2 \) level is approximately 60%, although in brain injured patients it may be somewhat higher. While the precise \( SjvO_2 \) threshold for cerebral ischemia may vary depending on the brain’s ability to extract oxygen, an \( SjvO_2 \) of < 50% for greater than 10 min has generally been considered to represent an ischemic desaturation.[46] High \( SjvO_2 \) levels may reflect hyperemia (typically >90%) or an inability of the brain to extract oxygen due to metabolic depression from sedative agents, poor oxygen unloading (e.g. sickle cell disease), or severe brain injury.[13] It should be noted that in certain situations, using \( SjvO_2 \) as a surrogate for \( AVDO_2 \) may be problematic. \( SjvO_2 \) may be influenced by hemoglobin levels and \( SjvO_2 \) may not reflect changes in cerebral oxygen extraction when extraction is intrinsically impaired or large areas of brain are already infarcted.[13,47]

It has been suggested that continuous, as opposed to intermittent, \( SjvO_2 \) monitoring is more effective in detecting significant changes in \( SjvO_2 \) levels.[48] Causes of low \( SjvO_2 \) include low CBF, low CPP, fever, and seizures. \( SjvO_2 \) monitoring has been used most commonly in patients with TBI or SAH for detection of reduced cerebral perfusion and by some to titrate hyperventilation in patients with increased ICP; other clinical applications include detecting arterio-venous fistulas and perioperative monitoring. An important caveat to \( SjvO_2 \) monitoring is that because it is a global monitor, regional ischemic changes may not be detected, and a relatively large volume of tissue must be affected before the \( SjvO_2 \) level drops significantly.[8,13]

Several studies have investigated the association between \( SjvO_2 \) monitoring and clinical outcome [Table 1]. Both abnormally high and low \( SjvO_2 \) levels have been associated with poor clinical outcome in TBI patients.[46,49-51] Early desaturations were most common in the first day post-TBI, and 90% of patients with multiple early desaturations had a poor clinical outcome, compared to 55% of patients without desaturations.[50] In one study of continuous \( SjvO_2 \) monitoring in 177 TBI patients, those with one or more episodes of desaturation had a higher likelihood of poor clinical outcome.[52] In another study in which historical controls were used to compare CPP-directed therapy versus CPP and \( SjvO_2 \)-directed therapy in a total of 353 patients, the \( SjvO_2 \) group had a significantly better outcome at six months.[43] Finally, \( SjvO_2 \) monitoring was used in a randomized trial comparing CBF-directed therapy versus ICP-directed therapy in patients with TBI. Overall, there was a significant decrease in the number of \( SjvO_2 \) desaturations in the CBF group (30% versus 51% in the CBF group). However, there was no difference in long-term clinical outcome, perhaps due to a four-fold increase in incidence of acute respiratory distress syndrome (ARDS) in the CBF-treated patients.[52] This randomized trial has provided important clarification that continuous monitoring of cerebral oxygenation can potentially be used to titrate aggressive systemic interventions designed to improved cerebral perfusion. These and other studies demonstrate a clear relationship between abnormal \( SjvO_2 \) levels and neurological outcome, but further randomized, prospective studies are needed to determine the optimal use of \( SjvO_2 \)-directed therapy to improve outcome.[42] Future directions for \( SjvO_2 \) monitoring include monitoring patients with other neurovascular or cardiac disorders and learning how to use \( SjvO_2 \) monitoring in the context of multi-modality monitoring.[42,53]
Cerebral microdialysis

Cerebral microdialysis is a neuromonitoring method that utilizes the capillary technique to measure the concentration of chemicals found in the brain parenchyma, with the goal of detecting neurochemical changes indicative of primary and secondary brain injury. The most commonly used system is the CMA600 microdialysis analyzer (CMA Microdialysis, Stockholm, Sweden); this system allows for semi-continuous measurement at the bedside of numerous parameters including glucose, glutamate, lactate, pyruvate, and glycerol concentrations. The microdialysis catheter consists of a fine tube within a semi-permeable dialysis membrane that allows for diffusion of molecules from the extracellular space along the catheter and into a small vial which is placed in the microdialysis analyzer. The catheter is inserted via a burr hole, often alongside P_{O_2} or ICP monitors. Ideally the microdialysis catheter is placed in the penumbra of the injured area or normal brain, but not directly in the injured brain. “Mock cerebrospinal fluid (CSF)” is instilled at a slow rate into the microdialysis catheter and then microdialysate is collected in a microvial. This process usually takes 20-30 min, resulting in some delay between real-time events and determined values. Also, microdialysis analysis is usually done intermittently (often hourly), which must be taken into consideration when interpreting microdialysis values. Complications from or detractions to cerebral microdialysis include detection of only focal changes in cerebral metabolism, difficulty in comparing quantitative values due to different catheter lengths and perfusate rates, disruption in brain tissue resulting in gliosis, spreading cortical depression, reduced CBF, flow-metabolism uncoupling, and hemorrhage. Another important limitation to microdialysis is the variability of results based on the location of the probe (in injured tissue, normal tissue, or areas of penumbra), bringing into debate the ideal location for catheter placement.

Substances that are regularly measured with cerebral microdialysis include glucose, a decrease of which may signify reduced cerebral perfusion, the lactate/pyruvate ratio and glutamate, which may reflect ischemic changes, and glycerol, which may indicate cell membrane breakdown. Several other neurotransmitters, energy-related metabolites, and markers of brain injury have been measured with cerebral microdialysis, and their clinical relevance remains under investigation. Although cerebral microdialysis has been largely used as a research tool, recently, the clinical utility of microdialysis has been recognized in the management of TBI, SAH, ischemic and hemorrhagic stroke, as well as perioperatively. A recent consensus meeting on cerebral microdialysis recommended its use in cases of severe TBI which also require ICP/CPP monitoring. Pathologic alterations in cerebral microdialysate have been correlated to changes in other metabolic parameters, including P_{O_2}, S_{jvO_2}, ICP, blood pressure, hypoxia, and CBF as measured by xenon CT or oxygen extraction fraction as measured by PET and have also been reported during nonconvulsive seizures. Finally, TBI and SAH patients with poor clinical outcome have been shown to have elevated levels of neurotransmitters, elevated lactate/pyruvate ratios, and abnormal lactate and glutamate levels. One of the largest studies using microdialysis included 126 TBI patients and showed a correlation between increased lactate/glucose ratio and lactate levels and increased mortality rates, as well as S_{jvO_2} desaturations. Other groups have suggested that microdialysis can provide useful information regarding glucose management in critically ill neurological patients and that alterations in cerebral metabolism detected by microdialysis may be independent of other parameters such as CPP. Because of the lack of randomized trials using microdialysis, further study is needed to determine the utility of cerebral microdialysis in consistently detecting secondary brain injury and how it may direct prospective management to improve outcome.

Cerebral blood flow

Cerebral blood flow has historically been considered as the most important physiologic parameter in the setting of brain injury, as CBF reflects delivery of substrate to tissue. Normal average CBF in the human is approximately 55 ml/100g (of brain)/min, but actual values may vary widely across grey and white matter. The ischemic threshold for CBF is approximately 18 ml/100g/min, with 10 ml/100g/min often considered the threshold for irreversible injury. CBF is influenced by mean arterial pressure, ICP, and the partial pressure of carbon dioxide and oxygen. These relationships bring forth the important principle of CBF and cerebral metabolic coupling, where CMRO_2 is directly related to CBF and AVDO_2. Historically, CBF was one of the first cerebral physiologic parameters to be measured and numerous techniques have been used for its measurement. However, only recently have commercially available continuous CBF neuromonitoring tools become available which may also be of practical use in the neurological intensive care unit.

Two such techniques are thermal diffusion flowmetry (TDF) and laser Doppler flowmetry (LDF). TDF is based on the principle of thermal conductivity of cortical tissue, where the temperature difference between two Silastic probes is detected and converted to quantitative CBF. Commerically available TDF microprobes include the QFlow 500 Probe and Bowman Perfusion...
Monitor (Hemedex Inc., Cambridge, MA, USA) and the Saber Cerebral Blood Flow Monitoring System (Flowtronics Inc., Phoenix, AZ, USA). Studies have found that CBF measured by thermal diffusion flowmetry correlates with CBF measured by other methods such as xenon CT. However, current TDF probes provide only a single focal CBF measurement from the area near the probe and remain less reliable than other conventional measures of CBF, tending to give higher measurements. Inaccurate measurements can also occur in the case of artifact after placement, large surface vessels, and loss of tissue contact; there is also concern of reliability of measurements and perhaps even safety in the context of fever.

Laser Doppler flowmetry involves a probe which is directly inserted into the brain parenchyma or over the surface of the brain, and is able to detect density measurements of moving blood, thereby providing momentary percentage changes in local CBF.[6] LDF does not provide absolute quantitative values of CBF, but rather relative change. This limits its utility in the context of neuromonitoring. A few studies have demonstrated correlation of LDF measurements to CPP as well as other conventional measures of CBF.[72,73]

Another different and important noninvasive technique for continuous or intermittent measurement of CBF is transcranial Doppler ultrasonography (TCD). TCD measures flow velocities in large intracranial vessels and allows for detection of changes in CBF; it is most widely used for detection of vasospasm, but has the potential for other clinical applications.[7,13]

Although the focus of modern neuromonitoring is to continuously monitor cerebral physiologic and metabolic parameters to allow for timely management decisions, several intermittent neuroimaging techniques used to measure global changes in CBF are worthy of mention. One such technique is dynamic perfusion computed tomography (CT) or CT perfusion (CTP), where infusion of iodinated contrast and the concurrent acquisition of images using a helical CT multislice scanner in cine mode allow for the measurement of CBF, cerebral blood volume (CBV), and mean transit time (MTT). This technique, which is relatively fast and can be performed on most helical CT scanners, has many potential clinical uses including prognostication in TBI and detection of hypoperfused regions in TBI as well as SAH.[9] Furthermore, preliminary studies have correlated MTT measured by CTP to PbO2 in TBI patients, demonstrating the correlation between metabolic and physiologic measures in brain injury [Figure 3].[18] Stable xenon CT has also had substantial use in the measurement of regional and global CBF. This technique utilizes inhaled nonradioactive xenon and concurrent acquisition of CT images; CBF is then calculated using the Kety-Schmidt equation. With the advent of portable CT machines, CTP and xenon CT may potentially see expanding roles as neuromonitoring tools in the neurological intensive care unit. Finally, SPECT (single photon emission computerized tomography) and PET (positron emission tomography) provide images of quantitative cerebral perfusion and metabolic parameters (CBF, CMRO2, etc.), but are limited by lengthy studies, the necessity to transport sometimes unstable patients, and cumbersome technology which make them of limited utility as practical neuromonitoring tools.[9]

Interpreting data for advanced neuromonitoring

Even as monitoring of the brain has advanced substantially since the origins of critical care in the 1960s, the manner in which intensive care unit physiological data has been collected and analyzed has changed little. This has created a disconnect that is magnified by the substantial increase in continuous physiological data that is generated by new advanced neuromonitors. How to manage all the data is a major question from clinicians considering integrating advanced neuromonitoring devices into clinical patient care. This question is only beginning to be addressed.

The varying relationships found between specific parameters such as CPP, and CBF, PbtO2, ICP, FO2, in differing studies suggest that there are likely complex multivariate relationships between physiological variables. This makes intuitive sense but until recently has been difficult to investigate because of limitations in intensive care data acquisition and analysis. Recent studies have suggested that derived measures such as PRx (pressure reactivity index), ORx (oxygen reactivity index), and VS burden (area under the curve for a specific physiologic vital sign such as temperature or blood pressure) may be more informative than raw data and thresholds alone.[1,16,74-77] However, this type of
analysis requires improved methods of electronic data acquisition. Currently, most systems are locally made solutions, but some commercial systems are now being developed.[16]

Consideration is also being given to novel methods of integrating this complex multiparameter-based physiological data. In the fields of genetics and genomics, advanced informatics and statistical methods have been developed to deal with the large volume of data derived from microarrays. In many ways, the continuous multiparameter time-series physiological data in neurocritical care is analogous. Considered tools include using neural network modeling to determine the interrelationships between different measured parameters,[78] using multivariable regression techniques to assess the impact of several factors on one parameter,[79] and using hierarchical cluster techniques for neuromonitoring data analysis in order to construct physiologic data profiles to classify patients for diagnostic and treatment purposes.[80,81] One novel approach has used self-organizing heat maps, a tool used in genetic bioinformatics, to assess association between various physiological parameters and determine how they cluster across patients.[80,81] While the clinical utility of these advanced analyses remains to be clarified, these efforts represent an important first step in harnessing the large amounts of data generated by advanced neuromonitoring. Advances in real time, user-friendly data analysis and presentation must accompany advances in neuromonitoring device development in order to truly move individualized patient-tailored care forward in the neurointensive care unit.

Conclusions

With the advent of commercially available neuromonitoring techniques which can be routinely used in neurointensive care units, identifying the clinical utility for individual monitors and the complementary roles different techniques might play in multi-modality monitoring has become an increasing priority. As the ultimate goal of neuromonitoring is to assess neurological function and help predict as well as improve outcome, an important next step is to move beyond observational studies and conduct prospective, randomized studies to understand how goal-directed therapy can directly affect outcome in various disorders.[10] Finally, an essential future direction for the field of neuromonitoring is to address how to integrate this complex body of data, with the ultimate goal of translation to the bedside care of patients in the neurointensive care unit.[80]

References


Accepted on 17-09-2008
Source of Support: Nil, Conflict of Interest: None declared.